Catch up on all coverage from Revolutionizing Atopic Dermatitis.
The 5th annual RAD conference kicks off April 29, 2023, in Washington, DC.
When sessions, late-breaking research, and more concludes, there is no shortage of things to do in the nation’s capital.
The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.
Revolutionizing Atopic Dermatitis Conference Chair Jonathan Silverberg, MD, PhD, MPH, previews this weekend's conference in Washington, DC.
Catch up on coverage from the first day of Revolutionizing Atopic Dermatitis.
Among numerous sessions to be held this weekend at the Revolutionizing Atopic Dermatitis Conference in Washington, DC, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.
A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.
Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"
Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."
Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.
Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.
Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.
De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.
In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.
Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.
In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.
Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.
In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.
Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.
Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.
Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.
Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.
Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.
The drug was both safe and effective in patients ages 6 months to 5 years.
The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.
New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.